Elevated Amyloid Changes Memory Worries Before Dementia — SkimNews
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- SOKRATES researchers interviewed 50 people who learned they had elevated amyloid and 30 who received a “not elevated” result; nearly all of the elevated group perceived added dementia risk, while interpretations in the not-elevated group varied.
- Impact of Events Scale scores rose notably in the elevated-amyloid group two to three days after PET results compared with the not-elevated group, with particularly high scores among younger participants, women, and people reporting memory problems.
- Participants with elevated amyloid remained cognitively unimpaired, yet some became more worried about memory lapses; no depression, unremitting anxiety, or suicide followed, which the author links at least partly to pre-scan education and mood assessment.
- The not-elevated group included people who concluded they would never develop Alzheimer’s or ruled out dementia entirely, overlooking other causes such as Lewy Body disease and LATE.
- Amyloid PET reporting offered only “elevated” or “not elevated,” leaving patients asking whether they had “nine amyloids or 9,000 amyloids”; people want three metrics—the value, its place in the range, and translation into personal risk.
- Trailblazer 3, Lilly’s donanemab trial, will conclude in coming months; Eisai’s AHEAD is testing lecanemab and Roche’s PREVENtron is testing trontinemab in biomarker-positive, cognitively unimpaired people to see whether lowering amyloid slows the transition to dementia.
- A4 tested solanezumab against placebo and was unsuccessful, but established a foundation for the three current anti-amyloid trials.
Why it matters: Penn Memory Center clinicians and patients receiving amyloid PET results face a concrete treatment question as three anti-amyloid trials continue and Trailblazer 3 concludes in coming months. The 80-person SOKRATES comparison shows why clearer risk education matters: elevated results changed memory-related worry for some, while not-elevated results sometimes led people to dismiss other causes of dementia.
Ask SkimNews
